

## *Curriculum Vitae*

**Torsten Goldmann** Prof. Dr. rer. nat.  
d.o.b. July 22<sup>nd</sup>, 1965, in Beckum, Germany

**Contact** Forschungszentrum Borstel - Leibniz-Lungenzentrum

### **University Education**

1984-1992 Diploma, Westfälische Wilhelms-Universität zu Münster  
1992-1995 PhD thesis, Dept. of Developmental Biology, Westfälische Wilhelms- Universität zu Münster  
2005 Habilitation, University Lübeck

### **Scientific Career**

2011 – present PI, German Center for Lung Research, Airway Research Center North (ARCN)  
2005 – present Lecturer/ Venia legendi/ adjunct Professor, University of Lübeck: Experimental Medicine and Molecular Biology (Lübeck)  
1997 – present Principal Investigator, Research Center Borstel,  
1995 - 1997 PostDoc, Max-Planck-Institut für Biochemie Martinsried, Molecular Biology  
1992 – 1995 PhD Student, Fachklinik Hornheide, Münster  
Dr. rer. nat. Biology: Westfälische Wilhelms-Universität zu Münster  
1991 – 1992 Diploma Student, Dept. of Developmental Biology, Westfälische Wilhelms-Universität zu Münster

### **Professional Activities and Memberships**

2018-2022 Lead PI, DA Lung Cancer, German Center for Lung Research  
1999-2021 Membership German Society for Pathology, reference panel for TB-PCR  
2005-2020 Deputy Editor Diagnostic Pathology

### **Honors and Recognitions**

2018 Visiting Professor Earl A. Chiles Cancer Center Portland Oregon, USA  
2019 Keynote Lecture: TGF beta signaling in Non Small Cell Lung Cancer, Uppsala, Sweden  
2014 Keynote Lecture on the role of Immunohistochemistry and molecular pathology, Tblisi, Georgia  
2014 Keynote Lecture on molecular techniques in modern pathology, University of Yerevan, Armenia

### **Citation record**

*Total citations: 8668; h-index:49; h-index since 2017:31 (Google Scholar August 8th, 2022)*

## Top-10 selected Publications

Heyckendorf J, Marwitz S, Reimann M, et al., **Goldmann T\***, Lange C\*. Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model. (*\*shared senior authorship*) Eur Respir J. 2021 Feb 11:2003492.

**Goldmann T**, Schmitt B, Müller J, Kröger M, Scheufele S, Marwitz S, Nitschkowski D, Schneider MA, Meister M, Muley T, Thomas M, Kugler C, Rabe KF, Siebert R, Reck M, Ammerpohl O. DNA methylation profiles of bronchoscopic biopsies for the diagnosis of lung cancer. Clin Epigenetics. 2021 Feb 17;13(1):38.

**Goldmann T**, Marwitz S, Nitschkowski D, Krupar R, Backman M, Elfving H, Thurfjell V, Lindberg A, Brunnström H, La Fleur L, Mezheyeuski A, Mattsson JSM, Botling J, Micke P, Strell C. PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung. Cancer Immunol Immunother. 2021 Feb 12.

Marwitz S, Turkowski K, Nitschkowski D, Weigert A, Brandenburg J, Reiling N, Thomas M, Reck M, Drömann D, Seeger W, Rabe KF, Savai R, **Goldmann T**. The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC. Front Oncol. 2020 Jan 21;9:1550.

Nitschkowski, D Marwitz S, Kotanidou SA, Reck M, Kugler Ch, Rabe KF, Ammerpohl O, **Goldmann T**. Live and let die: epigenetic modifications of Survivin and Regucalcin in non-small cell lung cancer tissues contribute to malignancy. Clin Epigenet 11, 157 (2019).

Marwitz S, Heinbockel L, Scheufele S, Kugler Ch, Reck M, Rabe KF, Perner S, **Goldmann T\***, Ammerpohl O\*. Fountain of youth for squamous cell carcinomas? On the epigenetic age of NSCLC and corresponding tumor-free lung tissues (*\*shared senior authorship*). Int J Cancer. 2018 Dec 15;143(12):3061-3070.

Marwitz S, Heinbockel L, Scheufele S, Nitschkowski D, Kugler Ch, Perner S, Reck M, Ammerpohl O, **Goldmann T**. Epigenetic modifications of the VGF-gene in human Non-Small Cell Lung Cancer tissues pave the way towards enhanced expression. Clin Epigenetics 2017;9:123.

Marwitz S, Scheufele S, Perner S, Reck M, Ammerpohl O, **Goldmann T**. Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in Non-Small Cell Lung Cancer results in increased expression. Clinical Epigenetics 2017, 9:51

Marwitz S, Depner S, Dvornikov D, Merkle R, Szczygieł M, Müller-Decker K, Lucarelli P, Wäsch M, Mairbäurl H, Rabe KF, Kugler C, Vollmer E, Reck M, Scheufele S, Kröger M, Ammerpohl O, Siebert R, **Goldmann T\*** (*\*shared senior author*), Klingmüller U. Downregulation of the TGF- $\beta$  pseudoreceptor BAMBI in non-small cell lung cancer enhances TGF- $\beta$  signaling and invasion. Cancer Res. 2016 Jul 1;76(13):3785-801.

**Goldmann T**, Kugler Ch, Reinmuth N, Vollmer E, Reck M. PD-L1 copy number gain in Non Small Cell Lung Cancer defines a new subset of patients for anti PD-L1 therapy. Ann Oncol. 2016 Jan;27(1):206-7.